arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

BIOVIE INC.

BIVI
$1.21 ▼ -0.12 (-9.02%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
54 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
13
Health
Poor
Bearish
auto_awesome

Analytical Summary

BIOVIE INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -44.0% ↘
FCF / Share None
Trailing P/E —
Price / Book 0.9x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-5.09M
↓ -22.5% —
FCF / Share Free cash flow per share
$-0.99
↓ -76.1% —
Long-Term Debt Long-term obligations
$62.50K
— 0.0% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
2
Financial Health ↓
6
Cash Quality ↑
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 14 years · 54 quarters